Discontinuation of Dialysis After ¹⁷⁷Lu-PSMA Therapy in mCRPC With Malignant Obstructive Uropathy.
A major complication of advanced prostate cancer is malignant obstructive uropathy, a condition that can precipitate post-renal acute kidney injury and ultimately require hemodialysis intervention.
APA
Yerdes E, Kalender E (2026). Discontinuation of Dialysis After ¹⁷⁷Lu-PSMA Therapy in mCRPC With Malignant Obstructive Uropathy.. Clinical nuclear medicine. https://doi.org/10.1097/RLU.0000000000006441
MLA
Yerdes E, et al.. "Discontinuation of Dialysis After ¹⁷⁷Lu-PSMA Therapy in mCRPC With Malignant Obstructive Uropathy.." Clinical nuclear medicine, 2026.
PMID
41940836
Abstract
A major complication of advanced prostate cancer is malignant obstructive uropathy, a condition that can precipitate post-renal acute kidney injury and ultimately require hemodialysis intervention. We present a striking imaging example of a patient with metastatic castration-resistant prostate cancer (mCRPC) and dialysis-dependent renal failure who demonstrated marked tumor regression and discontinuation of dialysis following 177Lu-PSMA radioligand therapy.